Celgene Falls After Updates to 2017 Guidance, 2020 Targets -- Biotech Movers

 | Oct 26, 2017 | 9:23 AM EDT
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

celg

,

mnov

,

akao

Shares of Celgene Corp. (CELG) were down 15.7% to $100.75 on Thursday, Oct. 26, after the Summit, N.J.-based firm unveiled third-quarter numbers and updated its 2017 outlook and financial targets for 2020.

The company reported adjusted diluted earnings per share of $1.91, up 21% from the year-ago period. Revenue rose 10% to $3.29 billion.

Celgene adjusted its full-year 2017 revenue guidance to about $13 billion, compared with previously issued guidance of $13 billion to $13.4 billion. It now expects adjusted diluted EPS of $7.30 to $7.35, compared with $7.25 to $7.35.

"In consideration of certain market dynamics and recent pipeline events, we are updating our 2020 outlook, and remain confident in our ability to deliver industry leading growth," said Celgene CEO Mark J. Alles in a statement. "Over the coming months, we look forward to sharing data supporting our innovative, next generation pipeline products and significant growth drivers."

For 2020, the company now targets total net product sales of $19 billion to $20 billion, compared with above $21 billion previously. It is targeting adjusted diluted EPS above $12.50. The previous target was north of $13.

Meanwhile, shares of MediciNova Inc. (MNOV) rose 16.4% to $7.60 after the La Jolla, Calif.-based firm said its Phase 2b study of MN-166 (ibudilast) in progressive multiple sclerosis met both primary endpoints.

Among the other biotech stock movers was Achaogen Inc. (AKAO) . Shares were up 4.8% to $13.85 after the South San Francisco, Calif.-based firm submitted a  new drug application to the U.S. Food and Drug Administration  for plazomicin as a treatment for complicated urinary tract infections.

The firm said it plans to submit an application for registration in the European Union in 2018.

Columnist Conversations

Facebook had outstanding earnings and looks to continue upward, while HD is a strong breakout on volume and Ak...
Stock picking contests can be entertaining and can provide some interesting ideas but if you seriously want to...
Your Reality Check. Check out Real Money's Helene Meisler's latest podcast here. Subscribe to Meisler's T...
XBTUSD (Bitcoin) On 4/25 Bitcoin top ticked @ 9755.52 and then FELL. Our first short term support @ 8990 was...

BEST IDEAS

REAL MONEY'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.